regulatory inspection – Page 17

Ongoing Stability Sample Pull Misses and CAPA Requirements

Addressing Gaps in Ongoing Stability Programs: A Step-by-Step Approach In the realm of pharmaceutical manufacturing, ongoing stability program gaps can have significant implications for product quality, regulatory compliance, and patient…

How to Manage Ongoing Stability for Bracketed and Matrixed Products

Managing Gaps in Ongoing Stability Programs for Bracketed and Matrixed Products Managing ongoing stability for bracketed and matrixed pharmaceutical products is a critical component of quality assurance and regulatory compliance.…

Ongoing Stability Program Gaps in Multi-Strength Product Families

Addressing Gaps in Ongoing Stability Programs for Multi-Strength Product Families In the highly regulated pharmaceutical environment, ongoing stability program gaps within multi-strength product families can lead to significant compliance issues…

How to Trend Ongoing Stability Data for APR and PQR Reviews

Effective Methods to Address Ongoing Stability Program Gaps In the realm of pharmaceutical manufacturing, ongoing stability programs are critical to ensuring product quality throughout its lifecycle. Stability data trending must…

Ongoing Stability Testing Frequency Errors and How to Prevent Them

Addressing Frequency Errors in Ongoing Stability Testing Programs In the pharmaceutical industry, ongoing stability program gaps can lead to significant regulatory compliance challenges and potential risks to product quality. These…

Common Failures in Selecting Batches for Ongoing Stability Programs

Tackling Common Failures in Batch Selection for Stability Programs The ongoing stability program (OSP) is a critical component of pharmaceutical quality assurance, ensuring that drug products remain effective and safe…

How to Design an Ongoing Stability Program for Commercial Products

Creating an Effective Ongoing Stability Program to Address Common Gaps Managing ongoing stability program gaps in pharmaceutical manufacturing is critical for ensuring product quality and regulatory compliance. A robust stability…

Ongoing Stability Program Gaps That Lead to Regulatory Observations

Identifying and Addressing Gaps in Ongoing Stability Programs to Prevent Regulatory Issues Ongoing stability program gaps can pose significant regulatory risks in the pharmaceutical industry. When stability data is not…

Label Claim Case Study: Changing Storage Statement After Stability OOT

Understanding Storage Statement Changes After Stability Out-of-Trend Results In the dynamic landscape of pharmaceutical manufacturing, a situation often arises where stability data indicates out-of-trend (OOT) results, compelling the need to…

How to Write CAPA When Label Claim Evidence Is Inadequate

Creating Effective CAPA Documentation for Inadequate Evidence of Label Claims In the pharmaceutical industry, having robust documentation and processes in place is critical to ensuring product quality and regulatory compliance.…

Label Claim Justification for Medical Device Combination Products

Justifying Label Claims for Medical Device Combination Products The pharmaceutical landscape is increasingly integrating medical devices with combination products, which adds complexity to label claim justification. Professionals in manufacturing, quality…

How to Prepare a Stability Summary for Label Claim Approval

Essential Steps for Creating a Stability Summary for Label Claim Approval In the pharmaceutical industry, the preparation of a comprehensive stability summary is critical for securing approval of label claims.…